Regulatory consulting case studies
Delivering strategic regulatory consulting across the product life cycle
Encompassing over 1,000 experts across more than 100 locations we deliver customised, end-to-end regulatory solutions tailored to your needs.
Enabling a biotech enter US and EU markets with a rare neurodegenerative disease treatment
An Asia Pacific based biotech was developing a therapeutic treatment for a neurodegenerative
disorder. ICON Regulatory Consulting was engaged to support market entry.
disorder. ICON Regulatory Consulting was engaged to support market entry.
Regulatory problem-solving secures crucial extensions in pediatrics and rare disease
As a result of the comprehensiveness of the documentation and the efficient management of the process, the European Commission granted both indication extension and the additional year of market exclusivity.
Regulatory solutions for uncharted scientific waters
Some therapeutic areas, especially rare pediatric diseases, lack clear development guidelines. ICON’s Regulatory Consulting Solutions helped a pharma client gain global regulatory and payer alignment on novel endpoints for a rare neurodevelopmental disorder, boosting confidence ahead of pivotal trials.
Use of Real World Data to fulfil post-approval requirements
A large pharma company submitted a New Drug Application for a targeted therapy treating a rare tumour subtype. To support safe use, a companion diagnostic PMA was filed in parallel with the FDA’s CDRH.
Overcoming time zone and knowledge gaps to gain FDA IND study approval
A Europe-based biotech preparing for a phase 1/2a oncology trial turned to ICON for support during their first IND submission. With limited FDA experience, they relied on ICON to navigate the 30-day review period and respond quickly to agency requests.
CMC and local regulatory expertise deliver timely anti-cancer drug approval
An international biopharmaceutical company based in the EU contracted ICON to support a new biologic drug application in Canada for an anti-cancer therapy for diffuse large B-cell lymphoma (DLBCL) under advance consideration.
Eliminating enrolment delays to bring an AI-enabled SaMD to market
A medical device developer faced clinical evaluation timeline delays due to under-enrolment. Discover how the collaborative partnership between the sponsor and ICON’s Medical Device & Diagnostics Research team steered the study from patient enrolment to FDA submission and approval.
Exceeding expectations for late-stage rescue study success
ICON stepped in when a biopharma company required urgent rescue assistance with two phase 3 trials for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA).
RIM Data and System Assessment to ensure IDMP compliance
RIM System Configuration and Data Assessment is pivotal in regulatory business planning. It also helps in organising product registration process to track and manage all regulatory activities.
Overcoming activation and enrollment delays
ICON partnered with a drug development sponsor to conduct a global programme for Multiple sclerosis (MS) studies in over 2,200 patients.
.jpg?crop=yes&w=2016&h=1060&a=0,142&itok=buBmlSsX "Boardroom meeting for regulatory strategy"){kind=icon}
Regulatory Technology Services
Software companies are incentivised to implement their solutions as quickly as possible, often leaving clients in a situation where the regulatory technology does not support the business process.
Regulatory technology services
Software companies are incentivised to implement their solutions as quickly as possible, often leaving their clients in a situation where the technology doesn’t support the business process, users are frustrated, and return on investment is questionable.